Overview

• UK coverage on October 1 reports GP Dr Ana Pérez Ballesta’s warning that many people take omeprazole for years without a clear clinical reason, often as a so-called stomach protector.
• She points to observational links between prolonged use and reduced absorption of calcium, magnesium, iron and vitamin B12, with associated risks such as osteoporosis, anaemia and digestive infections including C. difficile and SIBO.
• Abrupt discontinuation may trigger rebound acid hypersecretion, so patients are advised to seek medical guidance on managing or tapering therapy rather than stopping on their own.
• The GP reiterates that PPIs are intended for conditions like reflux or esophagitis, gastric or duodenal ulcers, Helicobacter pylori eradication, and gastroprotection for those at high risk of GI bleeding on anti-inflammatories.
• NHS data show 73 million PPI prescriptions were dispensed in England in 2022–23 with omeprazole among the most prescribed drugs, while reports note the evidence of long-term harms is observational and no new regulatory action is announced.